Vireo Growth (VREOF) Change in Receivables (2020 - 2026)
Vireo Growth (VREOF) posted Change in Receivables of $1.1 million for Q1 2026, down 41.22% sequentially from $1.9 million in Q4 2025, and up 283.33% YoY from $286956.5 in Q1 2025.
Vireo Growth (VREOF) Change in Receivables (2020 - 2026) Analysis & Trends
Vireo Growth has reported Change in Receivables for 7 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Change in Receivables rose 283.33% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.8 million (up 896.59% YoY) and the FY2025 annual result came in at $6.1 million, up 488.6% from the prior year.
- Change in Receivables slipped to $1.1 million in Q1 2026 per VREOF's latest filing, from $1.9 million in the prior quarter.
- Over five years, Change in Receivables peaked at $2.9 million in Q2 2025 and troughed at -$2.4 million in Q4 2023.
- A 5-year average of $383347.8 and a median of $221437.0 in 2022 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2022 and 2024: Change in Receivables jumped 3260.33% in 2022, then sank 1326.77% in 2024.
- Over 5 years, Change in Receivables stood at -$1.6 million in 2022, then slumped by 43.75% to -$2.4 million in 2023, then soared by 151.16% to $1.2 million in 2024, then soared by 55.53% to $1.9 million in 2025, then tumbled by 41.22% to $1.1 million in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $1.1 million, $1.9 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Vireo Growth | 491.44 Mn | 349.14 Mn | 95.30 Mn | 13.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.10 Mn |
| Mar 31, 2026 | 1.10 Mn |
| Dec 31, 2025 | 1.87 Mn |
| Dec 31, 2025 | 1.87 Mn |
| Sep 30, 2025 | 1.88 Mn |
| Sep 30, 2025 | 1.88 Mn |
| Jun 30, 2025 | 2.91 Mn |
| Jun 30, 2025 | 2.91 Mn |
| Mar 31, 2025 | -600,000.00 |
| Mar 31, 2025 | -600,000.00 |
| Dec 31, 2024 | 1.20 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 669,306.00 |
| Sep 30, 2024 | 669,306.00 |
| Jun 30, 2024 | -493,536.00 |
| Jun 30, 2024 | -493,536.00 |
| Mar 31, 2024 | -348,817.00 |
| Mar 31, 2024 | -348,817.00 |
| Dec 31, 2023 | -2.35 Mn |
| Dec 31, 2023 | -2.35 Mn |